evoke study semaglutide Results from the EVOKE and EVOKE+ phase 3 studies - Evokeclinical trial Results from the EVOKE and EVOKE+ phase 3 studies Evoke Study Semaglutide: Unpacking the Alzheimer's Trial Results

EVOKEtrial readout The evoke study and its companion EVOKE Plus trial represent significant milestones in the investigation of semaglutide, an oral GLP-1 drug, for its disease-modifying potential in early-stage Alzheimer's disease5 Alzheimer's Readouts To Watch. These large-scale, randomised, double-blind, placebo-controlled trial initiatives aimed to compare the effects of oral semaglutide with a placebo in improving memory, thinking, and daily functioning in individuals diagnosed with mild cognitive impairment or early Alzheimer's disease作者：I Ciccone—Results from the EVOKE and EVOKE+ phase 3 studiesreported that oral semaglutide did not significantly reduce clinical progression in patients .... The evoke and evoke+ trials were the first of their kind to explore the neurological applications of this drug class.

The trials, initiated by Novo Nordisk, were designed to assess whether semaglutide has a positive effect on early Alzheimer's disease. With a combined enrollment of over 3,800 adults aged 55 to 85 years, these studies were the largest and longest GLP-1 trials ever conducted in a neurodegenerative disease context. The design of two large-scale, double-blind, placebo-controlled, phase 3 studies ensured rigorous scientific scrutiny. The primary goal was to determine if semaglutide could offer a meaningful benefit to patients facing this progressive condition.

However, recent topline results announced on November 24, 2025, have presented a complex picture. While treatment with semaglutide demonstrated an improvement in AD-related biomarkers, the EVOKE and EVOKE Plus trials did not meet their primary endpoint.Novo Nordisk announces topline results from the Evoke ... Specifically, semaglutide did not slow Alzheimer's disease progression as measured by clinical assessments. This outcome has led to reports indicating that Semaglutide did not treat Alzheimer's in the manner initially hoped for, and evoke study results were met with disappointment by some experts.

Despite not demonstrating superiority over placebo in slowing disease progression, the EVOKE trial readout and the EVOKE Plus trial data are still considered valuable. The research conducted provides critical insights into the role of GLP-1 agonists in neurodegenerative diseases. It's worth noting that the evoke and evoke+ trials were specifically testing semaglutide in participants aged 55 to 85 years with early forms of the condition“Theevoke studywas largely predicated on the idea that GLP‑1 agonists might reduce neuroinflammation and improve insulin signaling/glucose metabolism,” he .... The EVOKE trial excluded individuals with cerebrovascular pathology, while EVOKE Plus included them, offering a nuanced approach to patient selection within the studies.

The disappointment, however, is palpable.2025年10月15日—EVOKE:Testing semaglutide in people with early-stage Alzheimer's disease, including mild cognitive impairment. EVOKE+: Testing semaglutide ... Many had pinned hopes on semaglutide's disease-modifying potential, given its established efficacy in treating type 2 diabetes and obesity. The underlying hypothesis for the evoke study was that GLP-1 agonists might reduce neuroinflammation and improve insulin signaling and glucose metabolism, processes implicated in Alzheimer's disease.Design of two large-scale, double-blind, placebo-controlled, phase 3 studiesevaluating efficacy, safety, and tolerability of semaglutide in early-stage ... Ultimately, the Results from the EVOKE and EVOKE+ phase 3 studies indicated that semaglutide did not achieve this therapeutic goal in the tested population.A pooled analysis of semaglutide in adults aged ≥ 65 years

Novo Nordisk, a company dedicated to driving change to defeat diabetes and other serious chronic diseases, including Alzheimer's disease, continues its research endeavors. While this particular study has fallen short of expectations for slowing disease progression, the wealth of data generated from the EVOKE and EVOKE Plus trials will undoubtedly inform future research and development in the field of Alzheimer's disease treatment.evoke Novo Nordisk’s Rybelsus (oral semaglutide) has failed to demonstrate efficacy in a late-stage trial for Alzheimer's disease, marking a setback for GLP-1RA Alzheimer's hopes. Nevertheless, understanding why these GLP-1 Semaglutide trials failed to outperform placebo in slowing progression is crucial for advancing the scientific understanding of this complex disease.作者：A Atri·2022·被引用次数：27—evoke and evoke+ will be the first large-scale phase 3 trials(Ntotal = 3,680) to investigate the hypothesized neuroprotective disease-modifying ... The EVOKE and EVOKE+ results provide a critical benchmark for future investigations.